Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
survivin-targeted DC cell injection
- Development stage
- Phase 2
- Lead developer
- Tricision Biotherapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Survivin-targeted DC cell injection (also known as TRC-001) is an autologous dendritic cell-based cancer vaccine developed by Beijing Tricision Biotherapeutics. The therapy utilizes patient-derived dendritic cells that are loaded with antigens derived from survivin (BIRC5), a protein that inhibits apoptosis and is highly overexpressed in glioblastoma and various other cancers while remaining largely absent in healthy adult tissues. Once administered, these mature dendritic cells present survivin-specific epitopes to the patient's T cells, stimulating the production of cytotoxic T lymphocytes (CTLs) that specifically target and eliminate survivin-expressing tumor cells. It is currently being investigated in Phase II clinical trials as a postoperative treatment for patients with newly diagnosed glioblastoma to prevent recurrence and extend survival.
- Other names
- Survivin-targeted DC vaccineSurvivin-DC injection
02
Targets
Survivin-MHC (Baculoviral IAP repeat-containing protein 5-derived peptides presented on MHC class I/II)
Beyond the preview
Go deeper on survivin-targeted DC cell injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on survivin-targeted DC cell injection.